Evidence map›Paper›PMID 12616111›Full record

Trial reportAnnals of surgery2003

Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett's esophagus.

Pascual Parrilla, Luisa F Martínez de Haro, Angeles Ortiz, Vicente Munitiz, Joaquín Molina, Juan Bermejo, Manuel Canteras

Open access · greenAbstract readClinical TrialComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in Annals of surgery, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 12 pooled it
14.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 12 syntheses or guidelines pooled it, 237 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Magnitude and Time-Trend Analysis of Postendoscopy Esophageal Adenocarcinoma: A Systematic Review and Meta-analysis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus.The American journal of gastroenterology · 2016
    Guideline
  8. Guideline
  9. Guideline
  10. Treatment for Barrett's oesophagus.The Cochrane database of systematic reviews · 2010
    Pooled it
  11. Pooled it
  12. Pooled it
  13. Disintegrin and metalloproteinases (ADAMs) expression in gastroesophageal reflux disease and in esophageal adenocarcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2017
    Trial
  14. Trial
  15. Medical or surgical management of GERD patients with Barrett's esophagus: the LOTUS trial 3-year experience.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2008
    Trial
  16. Trial
  17. Trial
  18. Trial
  19. The Impact of Hiatus Hernia Size on Dysplasia Progression in Patients With Barrett's Esophagus.JGH open : an open access journal of gastroenterology and hepatology · 2026
    Article
  20. Review

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Pascual ParrillaDepartment of Surgery, University Hospital Virgen de la Arrixaca, El Palmar, Murcia, Spain. parricir@huva.es
Luisa F Martínez de Haro
Angeles Ortiz
Vicente Munitiz
Joaquín Molina
Juan Bermejo
Manuel Canteras
Hospital Universitario Virgen de la Arrixaca · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo compare the results of medical treatment and antireflux surgery in patients with Barrett's esophagus (BE). SUMMARY BACKGROUND DATA: The treatment of choice in BE is still controversial. Some clinical studies suggest that surgery could be more effective than medical treatment in preventing BE from progressing to dysplasia and adenocarcinoma. However, data from prospective comparative studies are necessary to answer this question.

methodsOne hundred one patients were included in a randomized prospective study, 43 with medical treatment and 58 with antireflux surgery. All patients underwent clinical, endoscopic, and histologic assessment. Functional studies were performed in all the operated patients and in a subgroup of patients receiving medical treatment. The median follow-up was 5 years (range 1-18) in the medical treatment group and 6 years (range 1-18) in the surgical treatment group.

resultsSatisfactory clinical results (excellent to good) were achieved in 39 of the 43 patients (91%) undergoing medical treatment and in 53 of the 58 patients (91%) following antireflux surgery. The persistence of added inflammatory lesions was significantly higher in the medical treatment group. The metaplastic segment did not disappear in any case. Postoperative functional studies showed a significant decrease in the median percentage of total time with pH below 4, although 9 of the 58 patients (15%) showed pathologic rates of acid reflux. High-grade dysplasia appeared in 2 of the 43 patients (5%) in the medical treatment group and in 2 of the 58 patients (3%) in the surgical treatment group. In the latter, both patients presented with clinical and pH-metric recurrence. There was no case of malignancy after successful antireflux surgery.

conclusionsThese results show that there are no differences between the two types of treatment with respect to preventing BE from progressing to dysplasia and adenocarcinoma. However, successful antireflux surgery proved to be more efficient than medical treatment in this sense, perhaps because it completely controls acid and biliopancreatic reflux to the esophagus.

Indexed as

AdenocarcinomaAdolescentAdultAgedAnti-Ulcer AgentsBarrett EsophagusChildEsophageal NeoplasmsEsophagoscopyEsophagusFemaleFollow-Up StudiesFundoplicationGastric Acidity DeterminationHistamine H2 AntagonistsHumansAnti-Ulcer AgentsHistamine H2 AntagonistsOmeprazole

Identifiers

PMID12616111
PMCPMC1514316
OpenAlexW2021782120

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.